Therapeutic Effects of Reduced Glutathione on Chronic Hepatitis B
Objective
This study aimed to assess how reduced glutathione, when combined with entecavir, affects liver function, fibrosis, and HBV-DNA clearance in patients with chronic hepatitis B.
Methods
We conducted a randomized controlled trial with 90 chronic hepatitis B patients. They were split into two groups:
- Control Group: Received standard entecavir treatment for 3 months.
- Observation Group: Received a combination of reduced glutathione and entecavir.
We measured liver function and fibrosis markers before and after treatment and recorded HBV-DNA clearance rates at various intervals. We also monitored for any side effects.
Results
The findings showed:
- Improved Liver Function: ALT levels decreased significantly more in the observation group.
- Better Fibrosis Outcomes: The observation group had greater reductions in fibrosis markers.
- Higher HBV-DNA Clearance Rates: The observation group achieved higher rates of negative HBV-DNA conversion at all time points.
- Fewer Side Effects: The observation group had a lower rate of adverse reactions compared to the control group.
Conclusion
Combining reduced glutathione with entecavir significantly enhances liver function, reduces fibrosis, and improves HBV-DNA clearance in chronic hepatitis B patients, with minimal side effects.
Value of Clinical Trials
Clinical trials are essential for developing safe and effective treatments. To make these benefits accessible, our AI-driven platform, DocSym, consolidates clinical protocols and research into a user-friendly resource for healthcare providers.
Practical Solutions for Healthcare
- Streamlined Operations: Our mobile apps facilitate scheduling, treatment monitoring, and telemedicine, improving patient care management.
- Enhanced Workflows: By utilizing AI, clinics can optimize their processes, reduce paperwork, and improve patient outcomes.
Discover how we can assist your practice at aidevmd.com.
